I wish to inform you that the Endocrine Society of Australia (ESA) and the Australian Paediatric Endocrine Group (APEG) have submitted to the Pharmaceutical Benefits Advisory Committee (PBAC) an application for growth hormone to be subsidised by the Pharmaceutical Benefits Scheme.  The process provides and invites submissions from the public to support the ESA/APEG application. I am writing to encourage you to write in strong support of this application because the voice of the consumer can shape the decision making process.

You may be aware that previous applications to the PBAC from two pharmaceutical companies were unsuccessful.  The ESA/APEG have taken on this task because of concern that the benefits of growth hormone replacement in adults who lack this hormone is beyond the financial reach of most patients.

In your letter, please explain why growth hormone should be subsidised. There is nothing quite as powerful as a personal testimony or one written by a partner, relative or close friend.  The portal for your submission is [http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-consumer-comments](http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-consumer-comments%22%20%5Ct%20%22_blank)

The Australia Pituitary Foundation will also provide a submission and will be contacting its members to do so as well.  The application will be reviewed by the PBAC at the November 2016 meeting. The closing date for submission is 5th October.  I have attached the agenda for this meeting and you will note the listing on page 20 as Somatropin with the ESA and the APEG listed as co –applicants. In the submission form, the medicine to which this submission relates is Somatropin which is the technical name for human growth hormone.

Please do not hesitate to contact me should need more information.

Kind Regards